Lowering the approval hurdles in Dimerix's (ASX:DXB) Phase 3 trial is expected to boost the success, value, and appeal of the company's kidney failure therapy, DMX-200, to potential US partners, according to a Feb. 9 note by Euroz Hartleys.
In January, the company said findings from the US Food and Drug Administration-funded Project Parasol showed that reduced protein in urine lowers the risk of kidney disease progression.
Dimerix requested a meeting with the US FDA to agree on the appropriate protein in urine endpoints for DMX-200 in the Action3 Phase 3 trial, which aims to test the medication in patients with focal segmental glomerulosclerosis, a form of kidney disease.
Euroz believes that as the FDA already approved the design of the company's Phase 3, any modifications during the meeting are optional and offer potential upside.
The firm maintained DXB's speculative buy rating and its AU$1.06 price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。